Jubilant Life Sciences is currently trading at Rs. 744.80, up by 23.30 points or 3.23% from its previous closing of Rs. 721.50 on the BSE.
The scrip opened at Rs. 749.00 and has touched a high and low of Rs. 749.55 and Rs. 741.25 respectively.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 749.55 on 21-Jul-2020 and a 52 week low of Rs. 230.00 on 25-Mar-2020.
Last one week high and low of the scrip stood at Rs. 749.55 and Rs. 653.55 respectively. The current market cap of the company is Rs. 11492.13 crore.
The promoters holding in the company stood at 50.68%, while Institutions and Non-Institutions held 29.78% and 19.54% respectively.
Jubilant Life Sciences’ subsidiary -- Jubilant Generics has received approval from the Drug Controller General of India (DCGI) to manufacture and market the investigational antiviral drug remdesivir for 100 mg/vial (lyophilized injection) for restricted emergency use in India for the treatment of severe COVID-19.
Jubilant’s remdesivir product will be marketed under the brand name ‘JUBI-R’ in India and will be made available in 100 mg vials (injectable). It would be administered intravenously in a hospital setting under the supervision of a medical practitioner. The company will distribute the drug in the Indian market through its distribution network and will be available by the first week of August 2020.
Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions.